Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 8/20 | 0.85 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.85 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.85 |
| ▸ | ALB | P02768 | 1/20 | 0.85 |
| ▸ | PGR | P06401 | 1/20 | 0.85 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.85 |
| ▸ | GHSR | Q92847 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (S)-Bicalutamide SCHEMBL29444530 | 0.92 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| (R)-Bicalutamide SCHEMBL29354880 | 0.92 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| (R)-Bicalutamide SCHEMBL3612 | 0.92 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| SCHEMBL16871158 | 0.92 | AR (0.85) | ARCYP2C19ABCB11ALBPGR | |
| Bicalutamide SCHEMBL1561110 | 0.92 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| Bicalutamide SCHEMBL29353850 | 0.92 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| Bicalutamide SCHEMBL1933417 | 0.92 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| (S)-Bicalutamide SCHEMBL5365801 | 0.92 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| SCHEMBL20843744 | 0.92 | AR (0.85) | ARCYP2C19ABCB11ALBPGR | |
| Bicalutamide SCHEMBL3611 | 0.92 | AR (1.00) | ARCYP2C19ABCB11ALBPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020142228-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-07-09 | — | — | WO | disclosed |
| US-20200188416-A1 | METHODS OF TREATING ADVANCED PROSTATE CANCER | CITY OF HOPE | 2020-06-18 | — | — | US | disclosed |
| US-8216571-B2 | Fully human anti-VEGF antibodies and methods of using | SCHERING CORPORATION (US) | 2012-07-10 | — | — | US | disclosed |
| US-20110097340-A1 | FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING | XOMA TECHNOLOGY LTD. | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110097340-A1 | FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING | VEGFA, KDR, FLT4 | AR 3248/4885CYP2C19 4860/4885ABCB11 4874/4885 |
| US-20200188416-A1 | METHODS OF TREATING ADVANCED PROSTATE CANCER | KLK3, AR, ACP3 | AR 2/4885CYP2C19 3049/4885ABCB11 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.